SCHEMBL30741323

SCHEMBL30741323

CCc1cc(Nc2ncnc(Nc3ccccc3NS(C)(=O)=O)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 2/20 0.62
▸ KDR P35968 2/20 0.62
▸ FGFR1 P11362 1/20 0.62
▸ FGFR2 P21802 1/20 0.62
▸ FGFR4 P22455 1/20 0.62
▸ EGFR P00533 15/20 0.61
▸ PTK2 Q05397 3/20 0.57
▸ INSR P06213 2/20 0.57
▸ IGF1R P08069 2/20 0.57
▸ ALK Q9UM73 2/20 0.57
▸ BMPR1B O00238 1/20 0.57
▸ PLK4 O00444 1/20 0.57
▸ GAK O14976 1/20 0.57
▸ ERN1 O75460 1/20 0.57
▸ STK10 O94804 1/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ FYN P06241 1/20 0.57
▸ NPM1 P06748 1/20 0.57
▸ FES P07332 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27091505 1.00 FGFR3 (0.62) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL27091335 0.90 EGFR (0.63) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL30741326 0.90 EGFR (0.59) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL27091452 0.90 EGFR (0.59) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL27091419 0.88 EGFR (0.59) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL30741318 0.88 EGFR (0.59) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL30741328 0.85 EGFR (0.63) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL27091332 0.85 EGFR (0.63) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL26906593 0.82 EGFR (0.69) EGFRINSRIGF1RALK
SCHEMBL27076089 0.82 EGFR (0.65) EGFRINSRIGF1RALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051940-A1 SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2024-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051940-A1 SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF EGFR, ERBB2, ERBB4 FGFR3 27/4885KDR 201/4885FGFR1 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback